Core Viewpoint - The announcement highlights the extension of the lock-up period for cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1: Lock-up Agreement - The company entered into a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical, which includes a lock-up commitment for a total of 9,584,500 H shares for a period of 6 months from the listing date [1] - The cornerstone investor currently holds 9,584,500 H shares, representing approximately 3.43% of the company's total issued H shares [1] Group 2: Extension of Lock-up Period - The cornerstone investor has agreed not to reduce their holdings of the relevant H shares from the end of the original lock-up period until December 31, 2025 [1] - The company interprets the extension of the lock-up period as a sign of the cornerstone investor's confidence in the company's ability to advance its technological research and achieve significant clinical milestones [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]
派格生物医药-B(02565.HK)：基石投资者作出自愿延长禁售期